ArticleThe journal of venomous animals and toxins including tropical diseases2025
Cnidarian toxins: omics approaches and recombinant proteins.
Article in The journal of venomous animals and toxins including tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diversity and Bioprospection of Functional Proteins from Sea AnemoneMarine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cnidarian venom toxins have attracted increasing interest due to their remarkable molecular diversity and pharmacological potential. Omics technologies - such as genomics, transcriptomics, proteomics, and metabolomics - have facilitated the identification of toxin-encoding genes, providing key insights into their evolutionary trajectories and structure-function relationships, which are essential for understanding their mechanisms of action and therapeutic value. Nevertheless, the functional validation and production of complex toxins remain challenging, particularly for those requiring intricate folding or post-translational modifications. Recombinant expression has emerged as a strategic alternative to traditional purification methods, enabling controlled toxin production and the possibility of modifying their properties through genetic engineering. In parallel, advances in synthetic biology, such as cell-free protein synthesis systems, are creating new opportunities for toxin characterization, although their industrial scalability remains limited. Computational tools, including those based on artificial intelligence, are beginning to support the prioritization and functional analysis of toxins identified through omics approaches. This review provides an updated overview of the advances, limitations, and future perspectives in cnidarian toxin research, highlighting their promising role as a valuable source of bioactive compounds with therapeutic and biotechnological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.